317 related articles for article (PubMed ID: 32142770)
1. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
Mehrpouri M; Momeny M; Bashash D
J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806
[TBL] [Abstract][Full Text] [Related]
4. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
5. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Mosleh M; Safaroghli-Azar A; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989
[TBL] [Abstract][Full Text] [Related]
6. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4.
Sheikh-Zeineddini N; Safaroghli-Azar A; Salari S; Bashash D
Eur J Pharmacol; 2020 Mar; 870():172821. PubMed ID: 31770526
[TBL] [Abstract][Full Text] [Related]
7. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
12. Ergolide, a potent sesquiterpene lactone induces cell cycle arrest along with ROS-dependent apoptosis and potentiates vincristine cytotoxicity in ALL cell lines.
Yami A; Hamzeloo-Moghadam M; Darbandi A; Karami A; Mashati P; Takhviji V; Gharehbaghian A
J Ethnopharmacol; 2020 May; 253():112504. PubMed ID: 31904493
[TBL] [Abstract][Full Text] [Related]
13. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
14. Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.
Safa M; Tavasoli B; Manafi R; Kiani F; Kashiri M; Ebrahimi S; Kazemi A
Tumour Biol; 2015 May; 36(5):3919-30. PubMed ID: 25589462
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
16. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
Scuto A; Kirschbaum M; Buettner R; Kujawski M; Cermak JM; Atadja P; Jove R
Cell Death Dis; 2013 May; 4(5):e635. PubMed ID: 23681230
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
Waibel M; Vervoort SJ; Kong IY; Heinzel S; Ramsbottom KM; Martin BP; Hawkins ED; Johnstone RW
Leukemia; 2018 Jan; 32(1):237-241. PubMed ID: 28914259
[No Abstract] [Full Text] [Related]
19. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]